2024年1月9日 · ABBV-383 （ TNB-383B ）是由艾伯维和 TeneoOne 共同开发的一款针对 BCMA + CD3 的双特异性抗体，采用 2:1 设计，保持细胞杀伤能力的同时，还能降低细胞因子的释放。

2022年8月27日 · ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with …

2023年11月2日 · ABBV-383 is an off-the-shelf, fully human B-cell maturation antigen (BMCA) X CD3 bispecific antibody with bivalent BCMA domain and low CD3 affinity that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.

2024年6月5日 · ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain. 1 ABBV-383 is being evaluated in a Phase 3, multicenter, randomized, open-label study compared with standard available therapies in ...

2024年6月5日 · ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high...

2022年11月15日 · ABBV-383 (formerly TNB-383B) is a BCMA × CD3 bispecific T-cell-redirecting antibody with 2 BCMA-binding domains and a low-affinity CD3-binding domain to potentially mitigate the incidence of cytokine release syndrome (CRS) and eliminate the need for step-up …

2024年5月29日 · ABBV-383 is a distinctive next-generation BCMA x CD3 bispecific antibody composed of 2 high-affinity BCMA-binding domains, a low-affinity CD3-binding domain designed to reduce cytokine release syndrome (CRS) risk, and a silenced Fc tail for an extended half-life allowing convenient dosing.

2022年11月23日 · ABBV-383 (previously known as TNB383B) is a monoclonal, B-cell maturation antigen (BCMA)-targeted, IgG4 bispecific antibody. 1 It features a low-activating CD3 receptor that preferentially activates effector T cells rather than regulatory cells and minimizes cytokine induction of T-cell activity. 1 ABBV-383 expresses a heavy and light chain ...

2022年11月1日 · Purpose: ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose ...

2024年10月18日 · ABBV-383 is a unique bispecific antibody engineered to target both myeloma and T cells within the immune system. It is also unique as it is given intravenously (via IV) instead of subcutaneously (via injection). It's referred to as a BCMA x CD3 bispecific antibody.